Pfizer 2026 guidance shows Metsera, Seagen deals will take time to pay off

Pfizer’s 2026 Guidance: A Look at the Challenges Ahead

Pfizer, one of the world’s largest pharmaceutical companies, has released its 2026 guidance, which forecasts modest growth amidst declining Covid product sales and patent expirations. The company’s shares were largely flat in premarket trading on Tuesday, reflecting the mixed outlook. Pfizer’s adjusted profit is expected to come in between $2.80 and $3 per share next year, slightly below analysts’ consensus estimate of $3.05 per share.

The company’s revenue is expected to total $59.5 billion to $62.5 billion, which would be largely flat compared to Pfizer’s new 2025 sales guidance of $62 billion. Analysts were expecting 2026 sales of $61.59 billion. The lackluster revenue outlook comes in part from declining sales of Pfizer’s Covid vaccine and antiviral pill Paxlovid, which are forecast to fall by about $1.5 billion year-over-year to $5 billion.

Challenges and Opportunities

Pfizer is facing significant challenges, including declining sales of its Covid products and patent expirations. The company’s patent expirations are primarily expected to occur in 2026 and 2028, with $17 billion in revenues impacted by patent and regulatory exclusivity expirations. Additionally, some of Pfizer’s blockbuster drugs, such as the pneumonia vaccine Prevnar, are facing more competition from rivals.

However, Pfizer is also investing in its pipeline, with recent acquisitions such as the $10 billion acquisition of the obesity biotech Metsera and the $43 billion tie-up for cancer drugmaker Seagen in 2023. These investments are expected to pay off in the long term, but for now, they are still in early-stage development. Pfizer’s CEO, Albert Bourla, remains optimistic about the company’s long-term prospects, stating that comments by the Food and Drug Administration around shots “don’t have merit” and are “not going to change the way we are looking at our long term investments in vaccines.”

Cost Savings and Restructuring

Pfizer is targeting more than $7 billion in cost cuts by 2027 and expects to deliver the majority of those savings by next year. The company exceeded its cost-saving goals for 2025 and is on track to meet its targets. Analysts note that the guidance likely reflects costs tied to the company’s recent acquisitions, including Metsera. JPMorgan analyst Chris Schott called the outlook “largely expected,” stating that the Covid headwinds and research and development investments will be partially offset by ongoing restructuring at the company.

Overall, Pfizer’s 2026 guidance reflects the challenges the company is facing, but also its commitment to investing in its pipeline and reducing costs. As the pharmaceutical industry continues to evolve, Pfizer is positioning itself for long-term growth and success. With its diverse portfolio of products and investments in new technologies, the company is well-equipped to navigate the changing landscape and deliver value to its shareholders.